Anti-obesity drugs, also known as weight-loss drugs, are pharmaceutical agents that reduce or control weight. Some anti-obesity drugs approved for long-term use produce moderate weight loss. Anti-obesity drugs affect the central nervous system to decrease appetite or increase feelings of satiety. Common side effects include dry mouth, insomnia, constipation, and increased heart rate. The global anti-obesity drug market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

The global anti-obesity drug market is expected to be flourished by increasing prevalence of obesity worldwide. Obesity has more than doubled since 1980 and continues to rise rapidly in various regions globally. More than 1.9 billion adults aged 18 years and older were overweight in 2016 and out of these over 650 million were obese. Obesity is associated with increased risk of chronic diseases like cardiovascular diseases, diabetes and certain cancer types. Thus, increasing cases of obesity will drive the demand for anti-obesity drugs during the forecast period.

Market Dynamics:

Increasing Prevalence of Obesity – The driver mentioned in the heading, increasing prevalence of obesity is expected to drive the anti-obesity drug market growth over the forecast period. As per WHO, globally in 2016, more than 1.9 billion adults aged 18 years and older were overweight and out of these over 650 million adults were obese. Obesity increases the risk of various chronic diseases and it needs to be controlled. This increasing obesity cases is anticipated to boost the demand for anti-obesity drugs during the forecast period.

New Product Launches – Launch of new innovative anti-obesity drug therapies is another driver contributing to the anti-obesity drug market growth. Key pharmaceutical players are involved in research and development activities to develop new and improved anti-obesity drugs with minimal side-effects. Recently, some new drug therapies have been approved which will drive the market during the forecast period.

Segment Analysis

The global Anti-Obesity Drug Market Growth is segmented based on mechanism, distribution channel, and geography. Based on mechanism, the market is further categorized into peripheral adrenergic receptors, serotonin receptor 2C modulators, lipase inhibitors, and others. Among these, the peripheral adrenergic receptors segment dominates the market and accounts for around 30% share owing to the availability of wide range of drugs that act on peripheral adrenergic receptors to control obesity. The lipase inhibitors segment is expected to witness fastest growth over the forecast period 2023-2030 as drugs belonging to this segment curb fat absorption in the intestine.

PEST Analysis

Political: Governments across various countries are undertaking initiatives and programs to provide affordable healthcare along with raising awareness regarding lifestyle-related diseases such as obesity. This is expected to boost the demand for anti-obesity drugs.
Economic: Rising disposable incomes have led to changing food habits and sedentary lifestyles resulting in increased rate of obesity globally. This presents an attractive opportunity for growth of anti-obesity drug market.
Social: Obesity is associated with various social stigmas. However, growing awareness among public regarding its health risks is prompting more people to seek medical treatment for losing weight in a healthy manner. This is positively impacting the market.
Technological: Advances in drug research and development activities have facilitated development of novel anti-obesity drug formulations and drug delivery mechanisms with improved efficacy and safety profile. Continuous focus on R&D presents new avenues for market expansion.

a

The global Anti-Obesity Drug Market Growth is expected to witness high growthover the forecast period 2023-2030.

Regional analysis: North America holds the largest share currently owing to well-developed healthcare sector and growing obesity rates in the region. However, Asia Pacific region is poised to register fastest growth ascribable to rising healthcare expenditure, large patient pool, and increasing awareness about management of obesity-related risks.

Key players operating in the anti-obesity drug marketare ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it